17th International Conference on Pharmacovigilance

From Verify.Wiki
Jump to: navigation, search
Wizard photo 17th International Conference on Pharmacovigilance 1.png
17th International Conference on Pharmacovigilance
Date 2019-10-14
Place Miami, Usa.

The “International Conference on Pharmacovigilance” is going to be held on October 14-15, 2019 at Miami, USA. Pharmacovigilance conference gathers renowned scientists, physicians, surgeons, young researchers, industrial delegates and talented student communities in the field of cosmetology & dermatology under a single roof where networking and global partnering happens for the acceleration of future research. The 17th International Conference on Pharmacovigilance is organizing an outstanding Scientific Program, Exhibition and anticipates the world's leading specialists involved in and the organizing committee anticipates over 200 participants to attend this premier event. This conference is supported by the worldwide Editorial Board Members of Pharmaceutical Science and Energing Drugs, Journal of Regenerative Medicine.

Top Photos


Meetings International proudly announces the 17th International Conference on Pharmacovigilance scheduled during October 14-15, 2019 at Miami, USA. Pharmacovigilance conference gathers renowned scientists, physicians, surgeons, young researchers, industrial delegates and talented student communities in the field of cosmetology & dermatology under a single roof where networking and global partnering happens for the acceleration of future research. The conference emphasizes the theme “CURRENT CHALLENGES AND INNOVATIONS IN PHARMACOVIGILANCE”. Meetings International provides an international dais for scientists and Biomedicine and Biosimilars professionals to Exchange Ideas, Knowledge and Networking at its 100+ International Conferences. The importance of Pharmacovigilance has come into the spotlight in recent years. The main objective of Pharmacovigilance 2019 is to Understand the current developments, application, and challenges of Pharmacovigilance and Pharmaceuticals within Cosmetology and Dermatology. Sincerely, Operating Committee CEO and Founder Meetings International PTE LTD. Important Dates Early Bird: Registration Open: February 01, 2019 Abstract Submission Open: February 01, 2019 On Spot Registration: October 14, 2019.

Conference highlights

  • Pharmacovigilance Significance & Scope
  • Clinical Pharmacy and its Role in Treatment
  • Pre-Clinical and Clinical Trials
  • Clinical drug toxicity and biomarkers
  • Pharmacovigilance for herbal medicines
  • Pharmacoepidemiology
  • Serotonin pharmacology
  • Pharmacogenetics and pharmacogenomics
  • NanoPharmaceuticals
  • Nursing Pharmacology
  • Biomedical Science
  • Pharmacovigilance and Risk Management Planning
  • Pharmacy Technicians and Assistants

Who should attend?

  • All Stake Holders (both Academia & Industry) within the Pharmaceutical field
  • Researchers & Innovators
  • Experts Looking for Collaborative Work
  • Product Developers
  • Solution Providers
  • Sales & Marketing Professionals
  • Associations, Societies, & Professional Bodies
  • Funding Agencies & Fund Raisers
  • Management Bodies
  • Decision Makers

Why should attend?

Be the first to showcase your research, innovation and brand to gain competitive advantages. Meet your target audience and explore your product and services. Learn about the latest updates and news within the sector.

  • To Meet Experts
  • Learning In a New Space
  • New Tips & Tactics
  • Certification
  • Global Networking
  • Rebuild New Customer Base
  • Brand Establishment
  • Listen to the the top notch Pharma/Biotech Industry pioneers who will deliver the latest cutting edge information.
  • A fantastic opportunity to network with the top notch Pharma/Biotech Industry pioneers during the networking sessions.
  • Speak out sessions and Panel discussions will provide a great opportunity to ask questions from the expert and find out feasible solutions.

Contact information

Julie Tay Program Director| Pharmacovigilance 2019

Meetings International Pte Ltd 28 Maxwell Road, 03-05 Red Dot Traffic, Singapore (069120)

Contact: 6531080483 E-mail: pharmacovigilence@annualmeetings.net

Scientific sections

Track 1: Pharmacovigilance Significance & Scope Pharmacovigilance, as defined by the World Health Organization, comprises the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects and other drug-related problems. The aim of pharmacovigilance processes is to collect information about various broad aspects of medicinal product safety. These aspects are listed in the guidance document on good pharmacovigilance practices of the Food and Drug Administration (FDA). Global pharmacovigilance market was valued USD 2.5 billion in 2014. The revenue of this market is projected to increase at CAGR of 13% during the forecast period. North America is the leading market for pharmacovigilance market globally with the largest market in 2014.

Track 2: Clinical Pharmacy and its Role in Treatment Clinical pharmacy is a branch of pharmacy that involves the provision of patient care with the use of medications to optimize the health outcomes of patients. This includes promoting wellness and preventing disease. The practise of clinical pharmacy embraces pharmaceutical care philosophy. Clinical pharmacists are the experts in the therapeutic use of medicines in the healthcare team. Over the past four decades, the role of the pharmacist has evolved from an individual who was primarily responsible for safely and accurately distributing a medication product to a patient, to an individual who works side-by-side with physicians, nurses, and other healthcare professionals in sophisticated, highly specialized practise settings to assure appropriate medication therapy management.

Track 3: Pre-Clinical and Clinical Trials Clinical research is medical research involving people. There are two types, clinical studies, and clinical trials. Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioural intervention. They are the primary way that researchers find out if a new treatment, like a new drug or diet or medical device (for example, a pacemaker) is safe and effective in people. Often a clinical trial is used to learn if a new treatment is more effective and/or has less harmful side effects than the standard treatment. Pre-clinical trials are performed to GLP and cover pivotal toxicology & safety pharmacology studies. This phase continues once clinical trials have commenced establishing the long term safety of new chemical entities.

Track 4: Clinical drug toxicity and biomarkers Pharmacology intersects with toxicology when the physiological response to a drug is an adverse effect. A poison is any substance, including any drug that has the capacity to harm a living organism. Poisoning generally implies that damaging physiological effects result from exposure to pharmaceuticals, illicit drugs, or chemicals. Drug Toxicity is any Noxious and unintended response to the medicinal product if the medicine is properly prescribed and administered. Drug Toxicity is also called an adverse drug reaction (ADR). Biomarkers: A defining characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to exposure or intervention, including therapeutic interventions. Biomarkers can be classified based on different parameters, including their characteristics, such as imaging biomarkers (computed tomography, positron emission tomography, and magnetic resonance imaging) or molecular biomarkers.

Track 5: Pharmacovigilance for herbal medicines Herbal medicine has been known to be effective in the treatment of various ailments since the beginning of human civilization. Ayurveda is a form of herbal therapy originated in India. Plants, their parts, metabolites, and preparations are proven to have enormous therapeutic properties. The importance of herbal remedies in pharmacovigilance systems is becoming one of the primary tasks, due to the constantly ascending potential of herbal products and herbal medicines worldwide. Nowadays, the drug development is focused on finding new active compounds or combinations, but costs are simultaneously growing, which makes herbal medicines an attractive, harmless and cheaper alternative to synthetic drugs. Like all drugs, herbal is not free of risk and many studies suggest for potential adverse reactions and interactions. Available statistics show that some herbal products, used in traditional medication for generations, may possess carcinogenic, hepatotoxic, cardiotoxic and other severe actions.

Track 6: Pharmacoepidemiology Pharmacoepidemiology is the study of the use of and the effects of drugs in large numbers of people. The term pharmacoepidemiology obviously contains two components: "pharmaco" and "epidemiology." In order to better appreciate and understand what is and what is not included in this field, it is useful to compare its scope to that of other related fields. The scope of pharmacoepidemiology will first be compared to that of clinical pharmacology, and then to that of epidemiology.

Track 7: Serotonin pharmacology Serotonin (5-hydroxytryptamine) is an important biogenic amine that fulfils the role of neurotransmitter and neuromodulator. It has been a focus of interest during the last decade. Its diversity of pharmacologic actions is related to a wide variety of receptors and effector mechanisms. Seven serotonin receptor families have been identified thus far. They are genetically different transmembrane proteins composed of several hundred amino acids. Awareness of the serotonergic drugs and the recognition of possible drug interactions among drugs that influence serotonergic mechanisms in humans are becoming increasingly important in the practice of anesthesiology.

Track 8: Pharmacogenetics and pharmacogenomics Pharmacogenetics is the study of genetic differences in drug metabolic pathways that can influence individual responses to drugs, as well as side effects. Research in pharmacogenetics is currently developing in two main directions: firstly, identifying specific genes and gene products associated with various diseases, which may act as targets for new drugs, and, secondly, identifying genes and allelic variants of genes that affect our response to current drugs. Pharmacogenomics studies how medicine interacts with inherited genes. This includes how inherited genes affect the way medications work for each person. Genetic differences mean that a drug can be safe for 1 person but harmful for another. One person may experience severe side effects from it. Another may not even when given a similar dose.

Track 9: NanoPharmaceuticals Nanopharmaceuticals are colloidal particles of 10 to 1,000 nanometers (1 micron) in size. They are widely used in drug delivery. Nanopharmaceuticals are diverse both in their shape and composition and often offer an advantage as compared to their “bulk” counterparts primarily because of size. As a result, the properties of nanomaterials are fundamentally different from those of their macroscopic/ bulk analogues due to an increased surface area and quantum effects. As a particle’s size decreases, a greater proportion of its atoms are located on the surface relative to its core, often rendering the particle more reactive and more soluble in water.

Track 10: Nursing Pharmacology Pharmacology for Nursing introduces the science of pharmacology and considers the role of the registered nurse in the preparation, management, and administration of medications. Nursing Pharmacology is the investigation of how rules for medical attendants as to the substances that interfaces with living life forms to create an adjustment incapacity. It manages the examination, revelation, and portrayal of synthetic concoctions which indicate natural impacts and the enlightenment of cell and creature work in connection to these synthetic compounds. In the event that substances have therapeutic properties, they are viewed as pharmaceuticals. It includes instruments of medication activity, sedate structure and properties, associations, toxicology, treatments, restorative applications, and antipathogenic capacities.

Track 11: Biomedical Science Biomedical scientists focus on how cells, organs, and systems function in the human body; an exciting and dynamic area that is highly relevant to the understanding and treatment of human diseases. Biomedical scientists develop new treatments and therapies for human illnesses, diseases, and disabilities. Globally, more than US$240bn is spent on biomedical research and development every year (Guardian, 2018). The investment comes from private and public organizations to explore scientific solutions to health problems across the world.

Track 12: Pharmacovigilance and Risk Management Planning A medicinal product is authorized on the basis that in the specified indication(s), at the time of authorization, the risk-benefit is judged positive for the target population. However, not all actual or potential risks will have been identified when an initial authorization is sought. In addition, there may be subsets of patients for whom the risk is greater than that for the target population as a whole. The pharmacovigilance plan should be based on the safety specification and propose actions to address the safety concerns identified (relevant identified risks, potential, risks and missing information).

Track 13: Pharmacy Technicians and Assistants

Pharmacy Technicians are healthcare professionals who are registered with the General Pharmaceutical Council (GPhC) for their licence to practise. The title of Pharmacy Technician is protected in law and can only be applied to those who meet and maintain the professional standards set by the GPhC. Pharmacy assistants are other members of the pharmacy team who help support pharmacy technicians and pharmacists.

They can perform certain tasks assigned to them by the pharmacy technician or pharmacist but always do so under the direct supervision of the pharmacy technician or pharmacist. These may include tasks such as filing of pharmacy records, replenishing supplies and putting away drug orders.


Kalveer Flora Deputy Chair London North West University Healthcare NHS Trust, UK

Xavier Melo Celgene, Switzerland

Deepak Singh Pinnaxis, India

Albert M.Wu Doctor, Chang-Gung University, Taiwan

Amer Alghabban Vice President Gxp Compliance and Training Partners Limited, UK

Ripal Gharia Cliantha Research Limited, India

Abdeen Mustafa Omer, Occupational Health Administration, Ministry of Health, Sudan

Tentative program

Day 1
Registration 08:00-09:00
Session Introduction 09:00-09:15
Keynote/ Plenary Sessions
Plenary/Keynote-1 (Academia) 09:15-09:45
Plenary/Keynote-2 (Industry) 09:45-10:15
Plenary/Keynote-3 (Solution Provider) 10:15-10:45
Coffee Break & Networking 10:45-11:00
Plenary/Keynote-4 (Academia) 11:00-11:30
Oral Presentations
Speaker 1 11:30-11-:50
Speaker 2 11:50-12:10
Speaker 3 12:10-12:30
Speaker 4 (Industry presentation) 12:30-12:50
Panel Discussion/ QA Session 12:50-13:10
Lunch Break & Networking 13:10-14:00
Post Lunch Session Introduction & Group Photograph 14:00-14:10
Post Lunch Oral Presentations
Speaker 5 14:10-14:30
Speaker 6 (Industry Presentation) 14:30-14:50
Speaker 7 (Solution Providers Presentation X2) 14:50-15:10
Speaker 8 15:10-15:30
Panel Discussion/ QA Session 15:30-15:45
Video Sessions / e-Poster
Video Presentation 1 15:45-15:55
Video Presentation 2 15:55-16:05
Coffee Break & Networking 16:05-16:30
Workshop/ Special Session 16:30-17:00
Flash Talk/ Brain Strom Session
Flash Talk (X4) / Brain Strom (X4) 17:00-17:20
Award Ceremony/ Closing remark Day 1 17:20-17:30
Day 2
Registration 08:00-09:00
Session Introduction 09:00-09:15
Keynote/ Plenary Sessions
Plenary/Keynote-1 (Academia) 09:15-09:45
Plenary/Keynote-2 (Industry) 09:45-10:15
Plenary/Keynote-3 (Solution Provider) 10:15-10:45
Coffee Break & Networking 10:45-11:00
Oral Presentations
Speaker 1 11:00-11:20
Speaker 2 (Industry presentation) 11:20-11:40
Speaker 3 (Solution Provider X2) 11:40-12:00
Speaker 4 12:00-12:20
Panel Discussion/ QA Session 12:20-12:30
Workshop/Symposium 12:30-13:10
Lunch Break & Networking 13:10-14:00
Poster Presentation 14:00-14:45
Young Investigators Presentations
Speaker 5 14:45-15:05
Speaker 6 15:05-15:25
Speaker 7 15:25-15:45
Speaker 8 15:45-16:05
Panel Discussion/ QA Session 16:05-16:15
Coffee Break & Networking 16:15-16:30
Video Sessions/ e-poster 16:30-16:45
Award Ceremony/ Closing remark Day 2

About Miami

Miami is the second biggest city on the Atlantic coast of South Florida in the southeastern United States. As the seat of Miami-Dade County, the municipality is the principal, central, and the most populous city of the Miami metropolitan area and part of the second-most populous metropolis in the southeastern United States. A little more than a century ago, a city sprung up almost overnight. As a result, one of Miami’s many nicknames is the Magic City. Also, Miami is nicknamed the “Capital of Latin America “and is the largest city with a Cuban-American plurality. Miami is a major center, and a leader in finance, commerce, culture, media, entertainment, the arts, and international trade. This city is called Miami for the Miami river derived from Mayaimi. The Cuban influence is reflected in the cafés and tobacco shops of Calle Ocho in Little Havana. On the barrier islands, on the other side of the turquoise waters of Biscayne Bay, is Miami Beach, in which South Beach is located. This glamorous neighborhood is famous for its colorful art deco buildings, white sand, seaside hotels, and avant-garde clubs.

Verification history